INGELHEIM, Germany--(BUSINESS WIRE)--Today, Boehringer Ingelheim announced that the first patients have been enrolled in the company’s pivotal Phase III interferon (IFN)-free hepatitis C (HCV) clinical trial programme, HCVerso™. Boehringer Ingelheim’s IFN-free investigational polymodal* regimen combines faldaprevir (BI 201335)+, a next wave once-daily protease inhibitor, and BI 207127+, a non-nucleoside polymerase inhibitor, plus ribavirin.
